Immunotherapy in colorectal cancer.

Agarwal, Parul; Le, Dung T; Boland, Patrick M

Agarwal, Parul; Le, Dung T; Boland, Patrick M.

Affiliation

Agarwal P; Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, United States.
Le DT; Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, United States. Electronic address: dle@jhmi.edu.
Boland PM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.

Adv Cancer Res ; 151: 137-196, 2021.

Article in En | MEDLINE | ID: mdl-34148613

Subject(s)

Colorectal Neoplasms/therapy; Immunotherapy; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents, Immunological/pharmacology; Antineoplastic Agents, Immunological/therapeutic use; Colorectal Neoplasms/diagnosis; Colorectal Neoplasms/immunology; Humans; Immunotherapy/methods; Immunotherapy/trends; Prognosis; Tumor Microenvironment/drug effects; Tumor Microenvironment/immunology

Key words

CTLA-4; Colorectal cancer; Immune checkpoint blockade; Immunoscore®; Immunotherapy; Microbiome; Microsatellite instability; Neoantigen; PD-1; PD-L1; Tumor mutational burden

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Immunotherapy Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Adv Cancer Res Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google